ViOptix raises $12M for NRC-developed technology

ViOptix Inc, Fremont CA, has raised $12.2 million in series ‘D' financing to further commercialize its tissue oximetry technology for reconstructive microsurgery. The funding was provided by Channel Medical Partners, Lincoln Funds International and existing investors Canadian Medical Discoveries Fund and Morningside Technology Ventures Ltd. ViOptix also maintains operations in Toronto (ViOptix Canada) which holds an exclusive licence for tissue viability technology developed by the National Research Council's Institute for Biodiagnostics. ViOptix has raised $28.7 million since its inception in 1998. The latest financing will allow the firm to develop and launch additional clinical applications from its core technology platform and expand its presence in the microsurgery market....